Independent regulatory intelligence
Know the rules.
Understand the clinic.
Clear, sourced analysis of UK private clinic regulation, licensing and enforcement—for patients, practitioners and decision-makers.
The intelligence desk
Explore by section
From weekly regulatory movement to deeper enforcement and scientific analysis.
Regulatory Pulse
A weekly source-by-source scan of what changed in UK private clinic regulation — and what stayed the same.
3 articles
Enforcement Watch
Rulings, investigations and enforcement patterns affecting UK private clinics, pharmacies and healthcare advertising.
6 articles
Scientific Digest
New clinical research and evidence interpreted through the lens of UK private clinic safety and regulation.
9 articles
Guides
Evergreen guides to UK clinic licensing, legislation, prescribing rules and regulatory responsibilities.
4 articles
Regulatory Updates
Material UK regulatory, policy and medicine-approval developments with direct relevance to private clinics.
3 articles
Recently published
Latest analysis
-
MHRA: old patients are still the public
MHRA decisions show prescription-only medicine advertising risk across homepages, print, email, SMS and launch waitlists.
-
Botulism symptoms can take four weeks
MHRA repeats botulinum toxin safety warnings, including a four-week symptom window, as our weekly scan finds no other target-sector regulatory change.
-
GLP-1 exposure in early pregnancy: new study
A new claims study assessed GLP-1 continuation in early pregnancy, finding no definitive risk increase but wide uncertainty around several important outcomes.
-
Setting changes the odds after cosmetic Botox
A UK survey of 919 cosmetic Botox patients linked treatment setting, injector role and undisclosed products with different odds of reported adverse events.
-
Online pharmacy compliance goes beyond GPhC
A source-led guide to registration, governance, remote prescribing, medicine supply, advertising and Northern Ireland pharmacy regulation.
-
UK study compares semaglutide and dulaglutide
A UK primary-care cohort found greater one-year HbA1c and weight reductions with semaglutide than dulaglutide, with comparable safety overall.